

MIRA IV ACQUISITION CORP.

FORM 51-102F1 INTERIM MANAGEMENT'S DISCUSSION & ANALYSIS

Date

The following management's discussion and analysis ("MD&A") of the operations, results, and financial position of Mira IV Acquisition Corp. ("Mira IV"), dated May 29, 2015, covers the first quarter ended March 31, 2015 and should be read in conjunction with the unaudited interim financial statements of the Company for the same period, which were prepared in accordance with International Financial Reporting Standards. Additional information on the Company is also available on SEDAR at www.sedar.com.

Where we say "we", "us", "our", or the "Company" we mean MIRA IV Acquisition Corp. unless otherwise indicated. All amounts are presented in Canadian dollars unless otherwise indicated.

Forward-looking statements

Certain statements contained in this MD&A may constitute forward-looking statements. These statements relate to future events or the Company's future performance. All statements, other than statements of historical fact, may be forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "continue", "estimate", "expect", "may", "will", "project", "predict", "propose", "potential", "targeting", "intend", "could", "might", "should", "believe" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. The Company believes that the expectations reflected in those forward-looking statements are reasonable but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this MD&A should not be unduly relied upon by investors as actual results may vary. These statements speak only as of the date of this MD&A and are expressly qualified, in their entirety, by this cautionary statement.

In particular, this MD&A contains forward-looking statements, pertaining to the completion of the Transaction and the terms on which the Transaction is intended to be completed as well as the Company's ability to complete any qualifying transaction.

With respect to forward-looking statements above and otherwise contained in this MD&A, the Company has made assumptions regarding, among other things:

- *the legislative and regulatory environment;*
- *the impact of increasing competition;*
- *ability to obtain regulatory and shareholder approvals; and*
- *the Company's ability to obtain additional financing on satisfactory terms.*

The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of the risk factors set forth below:

- *volatility in the market conditions;*
- *incorrect assessments of the value of acquisitions;*
- *due diligence reviews; and*
- *competition for suitable acquisitions.*

The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of these risk factors set forth above.

Overall Performance

MIRA IV Acquisition Inc. is classified as a “Capital Pool Corporation” for the purposes of the policies of the TSX Venture Exchange (the “Exchange”). As a result, the Company’s current business is to identify and evaluate businesses and assets with a view to completing a “Qualifying Transaction”. Any proposed Qualifying Transaction must be accepted by the Exchange and in the case of a non-arm’s length Qualifying Transaction is also subject to “majority of the minority approval” in accordance with Policy 2.4 of the Exchange. The Company has not conducted commercial operations other than to enter into discussions for the purpose of identifying potential acquisitions or interests. The Company is not specifically considering pursuing a company, asset or business in any specific business or industry sector, or in any particular geographical area, and the Company has reviewed and anticipates it will continue to review companies, assets and businesses in a broad range of industry sectors and geographical areas.

Until completion of a Qualifying Transaction, the Company will not carry on any business other than the identification and evaluation of businesses or assets with a view to completing a potential Qualifying Transaction. With the consent of the Exchange, this may include the raising of additional funds in order to finance an acquisition. Except as described in the Company’s final prospectus dated August 12, 2014, the funds that will be raised pursuant to the Company’s initial public offering and any subsequent financing will be utilized only for the identification and evaluation of potential Qualifying Transactions and not for any deposit, loan or direct investment in a potential acquisition.

Proposed Qualifying Transaction

On November 5, 2014, the Company entered into a letter of intent, as amended, with Profound Medical Inc. (“Profound”), a corporation existing under the laws of the Province of Ontario, to complete a going-public transaction for Profound. [On April 29, 2015, Mira, Mira IV Subco Inc. \(a wholly owned subsidiary of Mira\) and Profound entered into an amalgamation agreement \(the “Amalgamation Agreement”\).](#)

[Pursuant to the Amalgamation Agreement](#), the proposed transaction will proceed by way of a three-cornered amalgamation under Ontario law, pursuant to which Profound will combine its corporate existence with [Mira IV Subco Inc.](#) For convenience, Mira, as it will exist after completion of the proposed transaction, is sometimes referred to herein as the resulting issuer.

Mira intends that the proposed transaction will constitute its qualifying transaction under TSX Venture Exchange Policy 2.4, Capital Pool Companies. The proposed transaction will be an arm’s-length transaction. [On May 21, 2015, the TSX Venture Exchange conditionally accepted the transaction with Profound as Mira’s qualifying transaction.](#)

Profound is a Canadian medical device company that is developing and commercializing a unique, minimally invasive treatment for prostate cancer. Profound’s novel technology combines magnetic resonance imaging (MRI) guidance and ultrasound energy to deliver thermal ablative therapy to the prostate gland. Delivered via a transurethral approach, the technique combines the image quality of MRI with thermal ultrasound as the treatment tool. This method of prostate cancer treatment affords highly accurate and precise treatment within the prostate gland in a short time span in an outpatient setting. Profound recently completed enrolment in its 30-patient multijurisdictional TULSA safety and feasibility trial.

In conjunction with the proposed transaction, [on April 30, 2015, Profound completed a brokered private placement of subscription receipts for gross proceeds of \\$24,008,827.50.](#) Each subscription receipt will be automatically exchanged for one common share of Profound immediately prior to the completion of the

proposed transaction and upon the satisfaction of specified escrow release conditions, including the completion or waiver of all conditions precedent to the proposed transaction.

Pursuant to the proposed transaction, it is intended that: (i) the outstanding common shares of Mira will be consolidated on the basis of one-post consolidation Mira common share for every 13.6363 pre-consolidation common shares of Mira; and (ii) the holders of Profound common shares (including those investors in the private placement) will receive one common share of the resulting issuer in exchange for each outstanding Profound common share (on a postconsolidation basis). The outstanding options of Mira will be adjusted accordingly to reflect the consolidation and one-third of options currently held by the directors of Mira will be cancelled. Following the completion of the proposed transaction, the shareholders of Profound (including those investors in the private placement) will hold a significant majority of the outstanding common shares of the resulting issuer.

For the purposes of the proposed transaction, the deemed value of each common share of Mira will be \$0.11 (on a preconsolidation basis).

Results of Operations for the period ended March 31, 2015

As at March 31, 2015, the Company had no operations other than identifying a qualifying transaction.

For the period ended March 31, 2015, Mira incurred operating expenses of \$52,102. These operating expenses are related to costs associated with the evaluation and negotiation of potential qualifying transactions, accounting and legal fees, listing fees and general and administrative expenses.

Stock-based compensation

For the period ended March 31, 2015, the Company recorded \$Nil in stock based compensation.

As the Company was incorporated on July 16, 2014, comparative data is not available.

Selected Financial Information

A summary of selected financial information as follows (as the Company was incorporated on July 16, 2014, comparative data is not available):

	For the period ended March 31, 2015
Interest income	\$358
Total expenses	\$52,460
Net loss	
- Total	\$(52,102)
- Per share	\$(0.01)
Total assets	1,661,609
Cash used in operations	\$(49,804)
Long-term financial liabilities	\$Nil

For the period ended March 31, 2015, the Company reported no discontinued operations and declared no cash dividends.

Detailed Quarterly Results

	From Incorporation (July 16, 2014) to September 30, 2014	Q4- 2014	Q1- 2015
Qualifying Transaction Expenses	\$31,631	\$166,509	\$38,808
Stock-based compensation	\$269,400	\$-	\$-
General and Administration Costs:			
Office and administrative	\$34,986	\$7,576	\$7,463
Professional fees	\$2,291	\$13,650	\$5,831
Loss for the period	\$338,308	\$187,735	\$52,102
Loss per share	\$0.03*	\$0.02*	\$0.01*

*based on 10,000,000 common shares issued on IPO and does not include escrowed shares as they are contingently returnable.

This summary of quarterly results should be read in conjunction with the financial statements and notes included in the Company's financial statements as at March 31, 2015.

Transactions with Related Parties

Related parties include the Board of Directors, close family members and enterprises which are controlled by these individuals as well as persons performing similar functions. As March 31, 2015, \$Nil (December 31, 2014 - \$2,177) is due to a company director.

There was no compensation to key management personnel.

Disclosure of Outstanding Share Data

At the date of this Discussion, the following is a description of the outstanding equity securities and exercisable securities previously issued by the Company:

	Authorized	Description of Securities
Voting or equity securities issued and outstanding	Unlimited Common Shares	20,000,000 Common Shares (deposited in escrow)
		10,000,000 Common Shares issued for cash on September 23, 2014
Securities convertible or exercisable into voting or equity securities - stock options	Stock options to acquire up to 10% of outstanding Common Shares	3,000,000 Stock options to acquire 3,000,000 Common Shares – granted on September 23, 2014
Securities convertible or exercisable into voting or equity securities - agent's option	Agent's options to acquire up to 1,000,000 common shares	1,000,000 Agent's option to acquire up to 1,000,000 common shares - granted on September 23, 2014
Voting or equity securities issuable on conversion or exchange of outstanding securities	(as above)	(as above)

On September 23, 2014, the Company completed an initial public offering of 10,000,000 common shares at a price of \$0.10 per share for gross proceeds to the Company of \$1,000,000 to purchasers in Ontario, Alberta and British Columbia. The agent received a cash commission of \$100,000 and the agent's legal fees and other disbursements. The agent was also granted a non-transferable option to acquire 10% of the aggregate numbers of shares sold pursuant to the offering for a period of 24 months from the date of listing of the common shares on the TSX Venture Exchange at an exercise price of \$0.10 per common share. The fair value assigned to these agent options issued is \$52,600. Share issue costs incurred with regards to this share issuance exclusive of the agent's commission amounted to \$155,100.

On September 23, 2014, the Company granted an aggregate of 3,000,000 stock options to directors and officers to purchase common shares, exercisable at a price of \$0.10 per share until September 23, 2014. The fair value assigned to these directors' and officers' options is \$269,400.

The following table summarizes the share purchase options outstanding and exercisable (convertible into one common share):

Number of Options	Exercise Price	Expiry Date	Weighted average remaining life (years)
1,000,000 ^(a)	\$ 0.10	September 23, 2016	1.48
3,000,000 ^(b)	\$ 0.10	September 23, 2024	9.48
4,000,000			

Recent Accounting Pronouncements

The following standard has been issued but is not yet effective:

- (a) IFRS 9, Financial Instruments ("IFRS 9") was issued in final form in July 2014 by the IASB and will replace IAS 39, Financial Instruments – Recognition and measurement ("IAS 39"). IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple rules in IAS39. The approach in IFRS 9 is based on how an entity manages its financial instruments in the context of its business model and the contractual cash flow characteristics of the financial assets. Most of the requirements in IAS 39 for classification and measurement of financial liabilities were carried forward unchanged to IFRS 9. The new standard also requires a single impairment method used, replacing the multiple impairment methods in IAS 39. IFRS 9 also includes requirements relating to a new hedge accounting model, which represents a substantial overhaul of hedge accounting which will allow entities to better reflect their risk management activities interest to non-financial institutions. IFRS 9 is effective for annual periods beginning on or after January 1, 2018. Early application is permitted.

The Company is currently evaluating the impact of the above standard on its financial performance and financial statement disclosures but expects that such impact will not be material.

Financial Instruments and Risk Factors

The Company's financial instrument consists of cash, accounts payable and accrued liabilities, and due to a director approximate fair values due to the relatively short term maturities of these instruments. It is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

Liquidity And Capital Resources

As at March 31, 2015, Mira had net working capital of \$1,536,154 (December 31, 2014 - \$1,588,256) comprised of cash, prepaid expenses, accounts payable and accrued liabilities, and due to its director. This included accounts payable and accrued liabilities of \$125,455 (December 31, 2014 - \$117,080) and due to a director of \$Nil (December 31, 2014 - \$2,177) which were due within 12 months, and cash of \$1,657,709 (December 31, 2014 - \$1,707,513) in the Company's bank accounts and in the solicitor's trust account. As a result, the Company is not exposed to the liquidity risk, and has sufficient funds to meet its ongoing obligations and to meet its objective of completing a Qualifying Transaction. Mira does not generate revenue from operations and any significant improvements in working capital would result from the issuance of share capital. Up to the date of this Discussion, the gross cash proceeds from the issue of share capital amounted to \$2,000,000.

The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the potential qualifying transaction. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company defines capital to include its working capital position and the capital stock, and option components of its shareholders equity.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.

There were no changes in the Company's approach to capital management during the period ended March 31, 2015. The Company is not a subject to externally imposed capital requirements.

Although economic conditions in the financial market appear to have made a modest recovery, it remains difficult under current economic conditions to secure debt or equity financing for some companies. If the current market conditions persist for an extended period of time, there can be no assurance that additional funding will be available to the Company or if available, that this funding will be on acceptable terms.

Critical Accounting policies and Estimates updated

Critical accounting estimates are those estimates that have a high degree of uncertainty and for which changes in those estimates could materially impact the Company's results. Significant items subject to estimates and assumptions include the valuation of stock options and the recognition of deferred income tax assets and liabilities. Actual results could differ from those estimates.

Additional Information

Additional information relating to the Company can be found on SEDAR at www.sedar.com.